A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
2026年6月9日 更新者:InnovStone Therapeutics Limited
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2072 Tablets in Healthy Participants
This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.
研究概览
研究类型
介入性
注册 (估计的)
112
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Clinical Trials Information Group officer
- 电话号码:+86-0311-69085587
- 邮箱:ctr-contact@cspc.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100029
- 招聘中
- Beijing AnZhen Hospital, Capital Medical University
-
接触:
- Yang Lin
- 电话号码:+86-18910778667
- 邮箱:linyang@anzhengcp.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
是的
描述
Inclusion Criteria:
- Participants must be fully informed about the study content, procedures, and potential adverse reactions, and voluntarily sign the written informed consent form (ICF) before the study;
- Sex: Male or female;
- Age: 18-55 years old (inclusive);
- Body mass index in the range of 19 to 30 kg•m-2 [Body Mass Index (BMI) = weight/height2 (kg•m^2)] (inclusive), with a body weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);
- Participants are able to communicate well with the investigator and are able to complete the study in accordance with the protocol.
Exclusion Criteria:
- History of severe allergic diseases or allergic constitution (allergy to ≥ 3 drugs or foods);
- Use of corticosteroid drugs within 3 months prior to screening;
- Past and/or current clinically significant medical conditions, including but not limited to diseases of the circulatory, hematologic or hematopoietic, respiratory, endocrine, urinary, digestive, nervous or psychiatric systems, infections, tumors, severe trauma, or any other disease that the investigator considers should be excluded or may interfere with the interpretation of the study results;
- Postural tachycardia (heart rate increase > 30 beats/minute upon standing) or postural hypotension (decrease in SBP ≥ 20mmHg or DBP ≥ 10mmHg upon standing) at screening;
- Have undergone major surgery within 6 months prior to screening, or plan to undergo major surgery during the study;
- Potassium ion level outside the normal range in clinical chemistry tests at screening, or serum creatinine > upper limit of normal (ULN);
- Any one of the following at screening: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) > 1.2×ULN (one re-test within 1 week is allowed);
- Estimated glomerular filtration rate (eGFR) < 90mL/min/1.73 m2 at screening;
- Prolonged QT/QTc interval at screening (QTcF ≥ 450ms for males, ≥ 470ms for females);
- Positive for any of the following: HBsAg, HCV antibody, syphilis antibody, or HIV antibody;
- Blood loss or blood donation exceeding 200mL within 3 months prior to screening (excluding menstruation for females), and/or platelet donation within 2 weeks;
- Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (including vitamins, health products, etc.) within 28 days prior to screening;
- History of drug abuse, and/or use of illicit drugs within 3 months prior to screening, and/or habitual use of any psychotropic drugs, including Chinese herbal medicines, and/or a positive urine drug screen;
- Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months prior to screening, and/or unwilling to avoid using any tobacco products during the study;
- Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol spirits or 150mL of 12% alcohol wine), and/or inability to abstain from alcohol intake during the study, and/or a positive breath alcohol test;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages (8 cups or more, 1 cup = 250mL) within 1 month prior to screening, and/or unwilling to abstain from tea, coffee, and/or caffeinated foods, grapefruit and/or grapefruit juice, and/or poppy-containing products during the study;
- Having a fertility plan (including sperm or egg donation) from the time of signing the ICF until 3 months after the last dose, and/or unwilling to use an effective non-drug method of contraception;
- Participation in any clinical study within 3 months prior to screening;
Participants who may be unable to complete the study for other reasons or who are deemed unsuitable for inclusion by the investigator.
In addition to the above requirements, female participants who meet the following criteria will also be excluded:
- Pregnant or lactating women;
- Use of oral contraceptives within 28 days prior to screening;
- Use of long-acting estrogen and/or progestogen injections and/or implants within 6 months prior to screening; 23)Women of childbearing potential who have had unprotected sexual intercourse with a partner within 28 days prior to dosing.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single Ascending Doses (SAD, Part A)
In this part, 6 ascending dose cohorts (10 participants per cohort) will be studied.
Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.
|
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 placebo tablets will be administered as a single or multiple oral doses.
|
|
实验性的:Food Effect (FE, Part B)
12 participants and single dose food effect cohort.
|
SYH2072 tablets will be administered as a single or multiple oral doses.
|
|
实验性的:Experimental: Multiple Ascending Doses (MAD, Part C)
In this part, 4 ascending dose cohorts (10 participants per cohort) will be studied.
Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.
|
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 placebo tablets will be administered as a single or multiple oral doses.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The rate of Adverse events
大体时间:Through study completion, an average of 8 months
|
The rate of Adverse events occur during the whole study
|
Through study completion, an average of 8 months
|
|
The rate of normality or abnormality of electrocardiogram
大体时间:Through study completion, an average of 8 months
|
The rate of normality or abnormality of electrocardiogram during the whole study
|
Through study completion, an average of 8 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年1月15日
初级完成 (估计的)
2027年2月1日
研究完成 (估计的)
2027年4月1日
研究注册日期
首次提交
2026年5月8日
首先提交符合 QC 标准的
2026年6月9日
首次发布 (实际的)
2026年6月15日
研究记录更新
最后更新发布 (实际的)
2026年6月15日
上次提交的符合 QC 标准的更新
2026年6月9日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他研究编号
- SYH2072-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.